Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis

Multiple Sclerosis and Related Disorders

Volumn 6, Issue , 2016, Pages 57-63

  Signori, Alessio ^a   Gallo, Fabio ^a   Bovis, Francesca ^a   Di Tullio, Nicolò ^a   Maietta, Ilaria ^a   Sormani, Maria Pia ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b Dep of Health Sciences (DISSAL)   (Italy)

Author keywords

Disability progression; Interferon beta; Long term; Meta analysis; Observational studies; Treatment effect

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO; IMMUNOLOGIC FACTOR; INTERFERON;

DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EARLY INTERVENTION; EXPANDED DISABILITY STATUS SCALE; HUMAN; IMMUNOMODULATION; META ANALYSIS; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT OUTCOME;

GLATIRAMER ACETATE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84962504312     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2016.01.007     Document Type: Article

References (24)

1. Bergamaschi R., Quaglini S., Tavazzi E., et al., 2012. Immunomodulatory Therapies Delay Disease Progression in Multiple Sclerosis, Mult Scler., (Epub ahead of print). doi: 10.1177/1352458512445941.
2. R.A. Bermel, B. Weinstock-Guttman, D. Bourdette, and et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study Mult. Scler. 16 2010 588 596
3. E. Cocco, C. Sardu, G. Spinicci, and et al. Influence of treatments in multiple sclerosis disability: A cohort study Mult. Scler. 21 2015 433 441
4. J. Drulovich, j Kostic, S. Mesarosa, and et al. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis Clin. Neurol. Neurosurg. 115 1 2013 S65 S69
5. A.N. Dreyer, P. Velentgas, K. Westrich, and R. Dubois The GRACE checklist for rating the quality of observational studies of comparative effectiveness: A tale of hope and caution J. Manag. Care Pharm. 20 2014 301 308
6. G.C. Ebers, A. Traboulsee, D. Li, and et al. Investigators of the 16-year long-term follow-up study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial J. Neurol. Neurosurg. Psychiatry 81 2010 907 912
7. D.S. Goodin, J. Jones, D. Li, and et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS PLoS One 11 2011 e22444
8. A. Gajofatto, M.R. Bianchi, L. Deotto, and M.D. Benedetti Are Natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study Eur. Neurol. 72 2014 173 180
9. J.P.T. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat. Med. 21 2002 1539 1558
10. A. He, T. Spelman, V. Jokubaitis, and et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis JAMA Neurol. 72 2015 405 413
11. L. Kappos, A. Traboulsee, C. Constantinescu, and et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS Neurology 67 2006 944 953
12. T. Kalincik, V. Jokubaitis, G. Izquierdo, and et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis Mult. Scler. 21 2015 1159 1171
13. T. Kalincik, D. Horakova, T. Spelman, and et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis Ann. Neurol. 77 2015 425 435
14. R. Lanzillo, M. Quarantelli, S. Bonavita, and et al. Natalizumab vs Interferon beta 1a in relapsing-remitting multiple sclerosis: A head-to-head retrospective study Acta Neurol. Scand. 126 2012 306 314
15. L. Patrucco, J.I. Rojas, and E. Cristiano Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients Rev Neurol. 50 2010 529 532
16. R.A. Rudick, G.R. Cutter, M. Baier, and et al. Estimating long-term effects of disease modifying drug therapy in multiple sclerosis Mult. Scler. 11 2005 626 634
17. A. Shirani, Y. Zhao, M. Karim, and et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis JAMA 308 2012 247 256
18. M.P. Sormani, and P. Bruzzi Can we measure long-term treatment effects in multiple sclerosis? Nat. Rev. Neurol. 11 2015 176 182
19. M.P. Sormani, L. Bonzano, L. Roccatagliata, and et al. Magnetic resonance imagin as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach Ann. Neurol. 65 2009 268 275
20. M. Trojano, F. Pellegrini, A. Fuiani, and et al. New natural history of interferon-beta-treated relapsing multiple sclerosis Ann. Neurol. 61 2007 300 306
21. M. Trojano, F. Pellegrini, Paolicelli, and et al. Real-Life Impact of Early Interferon Therapy in Relapsing Multiple Sclerosis Ann. Neurol. 66 2009 513 520
22. H. Tedeholm, J. Lycke, B. Skoog, and et al. Time to secondary progression in patients with multiple sclerosis treated with first generation immunomodulating drugs and historical controls, adjusted for clinical covariates Mult. Scler. 19 2013 765 774
23. P.J. Veugelers, J.D. Fisk, M.G. Brown, and et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: A longitudinal population-based evaluation Mult. Scler. 15 2009 1286 1294
24. Wells G.A., Shea B., O'Connell D., et al., 2000. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses, Paper Presented at 3rd Symposium on Systematic Reviews: Beyond the Basics Oxford.